Shots:

• Nimble Therapeutics spins out from Roche to commercialize its chemical synthesis drug discovery & development technology and has received $10M Series A funding from Telegraph Hill Partners
• The focus of spinning out Nimble Therapeutics is to expand Roche’s chemical synthesis technology by collaborating with other pharma companies to jointly develop drug candidates for multiple therapeutic areas
• The chemical synthesis technology harnesses the power of photolithography and an extensive library of photoprotected amino acids for synthesis & screening of peptides including scaffolded natural and modified macrocyclic peptidomimetics

Ref: Nimble Therapeutics | Image: Roche